ESCMID: Sanofi's Nuvaxovid COVID-19 vaccine showed better tolerability than mNEXSPIKE in head-to-head studyFirst head-to-head, double-blind, ...

Health Secretary Robert F. Kennedy Jr. on Wednesday concluded a marathon series of hearings with federal lawmakers, during ...

The European Commission has approved Moderna’s mCombriax, the first mRNA vaccine to combine protection against influenza and COVID-19 for adults aged 50 and above. The decision follows Phase 3 trial ...

The mRNA-based Covid vaccines helped blunt the impact of the pandemic but also sparked political backlash that has threatened ...

Kennedy acknowledged some HHS cuts are "painful" ...

Results from the phase 4 COMPARE study indicate that Nuvaxovid exhibits a more favorable reactogenicity profile compared with the mNEXSPIKE mRNA vaccine.

The Centers for Disease Control and Prevention (CDC) reportedly delayed the publication of its report detailing the benefits of the COVID-19 vaccine at the behest of its acting director. Acting CDC ...

This Verywell Health special report examines the latest research and initiatives aimed at addressing disparities in adult routine vaccinations.

Kennedy Jr., scientists at the Centers for Disease Control and Prevention have been blocked from publishing a scientifically vetted study finding significant health benefits from this season’s ...

Osteoarthritis affects around 600 million people globally. It causes pain, stiffness and reduced joint function – most commonly in the knees, hands and hips. There’s currently no cure for ...